Composition

Each Zoletech® vial contains:
Zoledronic Acid Monohydrate 4.264 mg (equivalent to 4.00 mg of Anhydrous Zoledronic Acid),
excipients: Mannitol, Sodium Citrate, q.s.

Each Diluent Ampoule contains:
Water for injections 5.00 ml.

Indications

Tumor-induced hypercalcemia: ZOLETECH is indicated for the treatment of tumor-induced hypercalcemia.

Multiple myeloma and bone metastases from solid tumors: ZOLETECH is indicated for the treatment of multiple myeloma and bone metastases from solid tumors in combination with standard antineoplastic therapy.

Prostate cancer: In patients with prostate cancer, ZOLETECH is indicated if the disease has progressed after treatment with at least one hormonal therapy.

Presentations

Lyophilized powder for infusion: packages containing 1 vial and 1 ampoule with water for injection.